The estimated Net Worth of Brian Douglas King is at least 556 千$ dollars as of 3 January 2022. Mr. King owns over 531 units of Novanta Inc stock worth over 368,235$ and over the last 8 years he sold NOVT stock worth over 0$. In addition, he makes 187,492$ as Independent Director at Novanta Inc.
Sign up
Mr. King NOVT stock SEC Form 4 insiders trading
Brian has made over 3 trades of the Novanta Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 531 units of NOVT stock worth 88,677$ on 3 January 2022.
The largest trade he's ever made was exercising 992 units of Novanta Inc stock on 2 January 2020 worth over 165,664$. On average, Brian trades about 368 units every 122 days since 2017. As of 3 January 2022 he still owns at least 2,205 units of Novanta Inc stock.
You can see the complete history of Mr. King stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Brian King biography
Brian D. King serves as Independent Director of the Company. Mr. King has been a Director of the Company since May 10, 2017. Mr. King is a senior advisor to Viant Medical, LLC, a private global services provider to the medical device industry, where he served as the President and Chief Executive Officer from May 2017 to July 2019. From June 2015 to March 2017, Mr. King served as an Operating Advisor for Thomas H Lee Partners, a private equity firm. From June 2014 to June 2015, Mr. King served as Chief Transformation Officer and Chief Operating Officer at DePuy Synthes, a Johnson & Johnson company, which designs and manufactures orthopedic and neurological devices and supplies. From 2004 to 2014, Mr. King served in various executive positions at Covidien, formerly Tyco Healthcare, a global healthcare products company and manufacturer of medical devices and supplies, which was later acquired by Medtronic. At Covidien, Mr. King served as Group President, Emerging Markets (2010-2014), President, Covidien Asia (2008-2010), Senior Vice President, Global Operations and Quality (2005-2008), and Vice President, Operational Excellence (2004-2005). Mr. King previously served on the board of directors of PCI Pharma Services, Houston Street Exchange, Inc., and B&C Research Corporation, all privately held entities. Mr. King holds an MBA from Harvard Business School, Master of Science from the Pennsylvania State University, and Bachelor of Science from the United States Naval Academy.
What is the salary of Brian King?
As the Independent Director of Novanta Inc, the total compensation of Brian King at Novanta Inc is 187,492$. There are 9 executives at Novanta Inc getting paid more, with Matthijs Glastra having the highest compensation of 4,058,920$.
How old is Brian King?
Brian King is 53, he's been the Independent Director of Novanta Inc since 2017. There are 5 older and 7 younger executives at Novanta Inc. The oldest executive at Novanta Inc is Stephen Bershad, 78, who is the Independent Chairman of the Board.
What's Brian King's mailing address?
Brian's mailing address filed with the SEC is C/O NOVANTA INC., 125 MIDDLESEX TURNPIKE, BEDFORD, MA, 01730.
Insiders trading at Novanta Inc
Over the last 9 years, insiders at Novanta Inc have traded over 115,059,741$ worth of Novanta Inc stock. The most active insiders traders include Stephen W Bershad、Ira J Lamel、Matthijs Glastra. On average, Novanta Inc executives and independent directors trade stock every 15 days with the average trade being worth of 1,701,396$. The most recent stock trade was executed by Robert Buckley on 3 September 2024, trading 4,379 units of NOVT stock currently worth 61,875$.
What does Novanta Inc do?
novanta (nasdaq: novt) delivers innovations that matter for its medical and advanced industrial oem customers. if you have a passion for solving complex technical problems that lead to breakthrough performance and that enhance people's lives, come join our growing team. here is a sample of the many exciting applications we serve: • innovations that ensure the safety of patients and efficient workflows in hospitals using our novel rfid technology • innovations in additive manufacturing, also known as 3-d metal printing, using our lightning fast lasers and laser beam steering sub-systems • innovations in minimally invasive surgery using our highly reliable insufflators, pumps and visualization systems • innovations in robotics and automation using our precision motors, encoders and drives for superior accuracy • innovations in smartphone production using our fast, accurate lasers and laser beam steering equipment along with our precision motion systems the driving force behind our grow
What does Novanta Inc's logo look like?
Complete history of Mr. King stock trades at Novanta Inc
Novanta Inc executives and stock owners
Novanta Inc executives and other stock owners filed with the SEC include:
-
Matthijs Glastra,
Chief Executive Officer, Director -
Robert Buckley,
Chief Financial Officer -
Matthijs Glastra,
CEO & Chairman -
Brian Young,
Chief Human Resource Officer -
Robert J. Buckley,
Chief Financial Officer -
Brian S. Young,
Chief HR Officer -
Stephen Bershad,
Independent Chairman of the Board -
Ira Lamel,
Independent Director -
Thomas Secor,
Independent Director -
Brian King,
Independent Director -
Lonny Carpenter,
Independent Director -
Deborah Eldracher,
Independent Director -
Ray Nash,
Corp. Fin. Leader -
Heinrich Dreyer,
Group Pres of Vision -
Charlie Webster,
Exec. VP of Novanta Growth System & Global Supply Chain -
Kitty Sahin,
Exec. VP of Strategy & Bus. Devel. -
Sarah Betadam,
Chief Information Officer -
Peter L. Chang,
Corp. Controller & Chief Accounting Officer -
Harry L Bosco,
Director -
John A Roush,
Chief Executive Officer -
Dominic A Romeo,
Director -
Dennis J Fortino,
Director -
Peter L Chang,
CAO-Corporate Controller -
Frank Anders Wilson,
Director -
Darlene J. S. Solomon,
Director -
Mary Kay Ladone,
Director -
Maxine Lum Mauricio,
Director -
Katherine Ann Owen,
Director -
Robert Matthew Johnson,
Director -
Barbara B. Hulit,
Director -
Michele Davis Welsh,
General Counsel